Vlad Ratziu1, Arun Sanyal2, Stephen A Harrison3, Vincent Wai-Sun Wong4, Sven Francque5, Zachary Goodman6, Guruprasad P Aithal7, Kris V Kowdley8, Star Seyedkazemi9, Laurent Fischer9, Rohit Loomba10,11, Manal F Abdelmalek12, Frank Tacke13,14. 1. Hôpital Pitié Salpêtrière and Sorbonne Université, Paris, France. 2. Department of Gastroenterology, Virginia Commonwealth University, Richmond, VA. 3. Pinnacle Clinical Research, San Antonio, TX. 4. Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, People's Republic of China. 5. Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium. 6. Center for Liver Diseases, Inova Fairfax Medical Campus, Falls Church, VA. 7. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK. 8. Liver Care Network, Swedish Medical Center, Seattle, WA. 9. Allergan plc, South San Francisco, CA. 10. Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA. 11. NAFLD Research Center, Department of Medicine, University of California, San Diego, La Jolla, CA. 12. Division of Gastroenterology & Hepatology, Department of Medicine, Duke University, Durham, NC. 13. Department of Medicine III, University Hospital Aachen, Aachen, Germany. 14. Department of Gastroenterology & Hepatology, Charité University Medical Center Berlin, Berlin, Germany.
Abstract
BACKGROUND AND AIMS: Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the 2-year CENTAUR study showed that CVC had an antifibrotic effect without impacting steatohepatitis. Herein, we report the final data from year 2 exploratory analyses. APPROACH AND RESULTS: This was a randomized, controlled study of adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH Clinical Research Network stage 1-3 fibrosis. Participants in arms A and C received CVC 150 mg or placebo, respectively, for 2 years; arm B received placebo in year 1 and switched to CVC in year 2. Liver biopsy was performed at baseline, year 1, and year 2. Of 289 randomized participants, 242 entered year 2. At year 2, 24% of patients who switched to CVC and 17% who remained on placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (P = 0.37). Twice the proportion on CVC who achieved fibrosis response at year 1 maintained benefit at year 2 (60% arm A versus 30% arm C), including 86% on CVC who had stage 3 fibrosis at baseline. Over 2 years, a similar proportion on CVC or placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (15% arm A versus 17% arm C). In patients with fibrosis responses, we observed consistent reductions in levels of N-terminal type 3 collagen propeptide and enhanced liver fibrosis scores, while increases in aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 scores were consistently observed in nonresponders. Safety profile was comparable across groups. CONCLUSIONS:CVC was well tolerated, and year 2 data corroborate antifibrotic findings from year 1. The majority on CVC who achieved fibrosis response at year 1 maintained it at year 2, with greater effect in advanced fibrosis. ClinicalTrials.gov number, NCT02217475 (CENTAUR).
RCT Entities:
BACKGROUND AND AIMS: Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the 2-year CENTAUR study showed that CVC had an antifibrotic effect without impacting steatohepatitis. Herein, we report the final data from year 2 exploratory analyses. APPROACH AND RESULTS: This was a randomized, controlled study of adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH Clinical Research Network stage 1-3 fibrosis. Participants in arms A and C received CVC 150 mg or placebo, respectively, for 2 years; arm B received placebo in year 1 and switched to CVC in year 2. Liver biopsy was performed at baseline, year 1, and year 2. Of 289 randomized participants, 242 entered year 2. At year 2, 24% of patients who switched to CVC and 17% who remained on placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (P = 0.37). Twice the proportion on CVC who achieved fibrosis response at year 1 maintained benefit at year 2 (60% arm A versus 30% arm C), including 86% on CVC who had stage 3 fibrosis at baseline. Over 2 years, a similar proportion on CVC or placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (15% arm A versus 17% arm C). In patients with fibrosis responses, we observed consistent reductions in levels of N-terminal type 3 collagen propeptide and enhanced liver fibrosis scores, while increases in aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 scores were consistently observed in nonresponders. Safety profile was comparable across groups. CONCLUSIONS:CVC was well tolerated, and year 2 data corroborate antifibrotic findings from year 1. The majority on CVC who achieved fibrosis response at year 1 maintained it at year 2, with greater effect in advanced fibrosis. ClinicalTrials.gov number, NCT02217475 (CENTAUR).
Authors: Batuhan Yenilmez; Nicole Wetoska; Mark Kelly; Dimas Echeverria; Kyounghee Min; Lawrence Lifshitz; Julia F Alterman; Matthew R Hassler; Samuel Hildebrand; Chloe DiMarzio; Nicholas McHugh; Lorenc Vangjeli; Jacquelyn Sousa; Meixia Pan; Xianlin Han; Michael A Brehm; Anastasia Khvorova; Michael P Czech Journal: Mol Ther Date: 2021-11-11 Impact factor: 11.454
Authors: Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden Journal: Nat Rev Gastroenterol Hepatol Date: 2021-05-10 Impact factor: 46.802
Authors: Jonathan G Stine; Nagambika Munaganuru; Abbey Barnard; Jennifer L Wang; Kellee Kaulback; Curtis K Argo; Siddarth Singh; Kathryn J Fowler; Claude B Sirlin; Rohit Loomba Journal: Clin Gastroenterol Hepatol Date: 2020-08-31 Impact factor: 11.382